Anthony G. Quinn, President & CEO at Aeglea BioTherapeutics, Inc. (AGLE), bought 289,332 shares at $2.06 ($562K) on 2022-03-11, disclosed to the SEC on 2022-03-15.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.06 | 34,777 | $72K | 12.8% |
| 2 | $2.06 | 34,777 | $72K | 12.8% |
| 3 | $1.93 | 67,472 | $130K | 23.2% |
| 4 | $1.93 | 67,472 | $130K | 23.2% |
| 5 | $1.86 | 42,417 | $79K | 14.1% |
| 6 | $1.86 | 42,417 |
| $79K |
| 14.1% |
| Total | $1.94 avg | 289,332 | $562K | 100% |
| Filing → |
| AGLE | BUY | 2022-03-18 | $375K | — | Filing → |
| AGLE | BUY | 2021-12-13 | $358K | — | Filing → |
| AGLE | BUY | 2020-05-04 | $784K | — | Filing → |